{
  "meta": {
    "title": "08_Inicet_Predictor_Series_Pharmacology",
    "url": "https://brainandscalpel.vercel.app/08-inicet-predictor-series-pharmacology-35fd7d81.html",
    "scrapedAt": "2025-11-30T06:48:51.782Z"
  },
  "questions": [
    {
      "id": 300858,
      "choices": [
        {
          "id": 1,
          "text": "1. B, 2D, 3D, 4C"
        },
        {
          "id": 2,
          "text": "1.C, 2.A, 3D, 4B"
        },
        {
          "id": 3,
          "text": "1. C, 2 D, 3.A, 4B"
        },
        {
          "id": 4,
          "text": "1.B, 2.A, 3.D, 4.C"
        }
      ],
      "text": "<p>Match the following</p><p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/2230644_Pharma-1.png\"></p>",
      "unique_key": "Q300858",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (D)\r\n\r\n1. Pirenzepine → M₁ muscarinic antagonist → used in gastric ulcer (B)\r\n\r\n2. Methacholine → Muscarinic agonist → bronchoconstrictor → diagnosis of asthma (A)\r\n\r\n3. Cevimeline → M₃ muscarinic agonist → increases secretions → Sjogren's syndrome (D)\r\n\r\n4. Bethanechol → Muscarinic agonist → stimulates bladder & GI motility → postoperative atony of intestine (C)\r\n",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300860,
      "choices": [
        {
          "id": 1,
          "text": "Brexpiprazole"
        },
        {
          "id": 2,
          "text": "Alprazolam"
        },
        {
          "id": 3,
          "text": "Rivastigmine"
        },
        {
          "id": 4,
          "text": "Memantine"
        }
      ],
      "text": "Which of the following drugs has been approved for the management of agitation associated with Parkinson’s disease?",
      "unique_key": "Q300860",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (A)\r\n\r\n• Brexpiprazole is an atypical antipsychotic that has received FDA approval for the treatment of agitation associated with dementia due to Alzheimer’s disease.\r\n\r\n• However, none of the listed drugs are specifically approved for agitation in Parkinson’s disease, but among antipsychotics, Quetiapine or Clozapine are often used off-label for psychosis/agitation in Parkinson’s, while Brexpiprazole is used in Alzheimer’s agitation.\r\n\r\n• Since the question asks which drug “has been approved for the management of agitation associated with Parkinson’s disease,” in reality none are officially approved for that indication.\r\n\r\n• But if the question is based on recent extensions or clinical trial data, Brexpiprazole is the only one among the options approved for agitation in a neurodegenerative disorder (Alzheimer’s), and sometimes exam questions may generalize this to Parkinson’s or consider it the closest match.\r\n\r\nGiven the options, Brexpiprazole is the most appropriate answer because it is the only one with an official agitation indication in dementia (though not specifically Parkinson’s).\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300862,
      "choices": [
        {
          "id": 1,
          "text": "A–1, B–2, C–3, D–4"
        },
        {
          "id": 2,
          "text": "A–2, B–1, C–3, D–4"
        },
        {
          "id": 3,
          "text": "A–3, B–1, C–4, D–2"
        },
        {
          "id": 4,
          "text": "A–4, B–1, C–2, D–3"
        }
      ],
      "text": "<p>Match the following drugs used in the management of Myasthenia Gravis with their respective mechanisms of action:</p><p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/677525_Pharma-2.png\"></p>",
      "unique_key": "Q300862",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (A)\r\n\r\n• Zilucoplan is a macrocyclic peptide that binds to complement C5, inhibiting its cleavage → prevents membrane attack complex formation.\r\n\r\n• Efgartigimod is an FcRn antagonist → reduces IgG levels by blocking IgG recycling.\r\n\r\n• Rituximab targets CD20 on B cells → depletes B cells → reduces autoantibody production.\r\n\r\n• Pyridostigmine is an acetylcholinesterase inhibitor → increases acetylcholine availability at neuromuscular junctions.\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300865,
      "choices": [
        {
          "id": 1,
          "text": "1, 2 & 3"
        },
        {
          "id": 2,
          "text": "2, 3 & 4"
        },
        {
          "id": 3,
          "text": "1, 3 & 4"
        },
        {
          "id": 4,
          "text": "3 & 4"
        }
      ],
      "text": "<p> Which of the following drugs act primarily through β-adrenergic receptors?<br></p><p>1. Dobutamine<br></p><p>2. Fenoldopam<br></p><p>3. Mirabegron<br></p><p>4. Dopexamine</p>",
      "unique_key": "Q300865",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (C) \r\n\r\n1, 3, and 4\r\n\r\n• Dobutamine → β1-adrenergic receptor agonist (also some β2 and α1 activity).\r\n\r\n• Fenoldopam → Selective D1 receptor agonist (dopaminergic), no β-action.\r\n\r\n• Mirabegron → β3-adrenergic receptor agonist (used for overactive bladder).\r\n• Dopexamine → β2-adrenergic receptor agonist (also dopaminergic D1 activity).\r\n",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300867,
      "choices": [
        {
          "id": 1,
          "text": "A & B"
        },
        {
          "id": 2,
          "text": "B & C"
        },
        {
          "id": 3,
          "text": " B & D"
        },
        {
          "id": 4,
          "text": "C & D"
        }
      ],
      "text": "<p>Which of the following drugs is NOT considered a first-line pharmacologic treatment for cardiogenic shock? <br></p><p>A. Norepinephrine (NE) <br></p><p>B. Dopamine <br></p><p>C. Dobutamine <br></p><p>D. Vasopressin</p>",
      "unique_key": "Q300867",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (C)\r\n\r\nBoth norepinephrine and dobutamine are considered first-line drugs in cardiogenic shock management. Dopamine is sometimes used but is associated with more adverse effects, so its use is more limited and less favored. Vasopressin is generally not considered first-line but rather a second-line or adjunct agent.\r\n\r\nTherefore, the drugs NOT considered first-line in cardiogenic shock are primarily \r\nD. Vasopressin, and to some extent B. Dopamine, depending on guidelines and clinical context \r\nSo the answer to the \"multiple answer\" format question would include both B and D as not first-line agents.\r\n\r\nSummary:\r\n• First-line drugs include Norepinephrine and Dobutamine.\r\n• Dopamine and Vasopressin are not generally first-line; Vasopressin especially is used as adjunct therapy in refractory cases.\r\nThis reflects contemporary clinical guidelines for cardiogenic shock treatment.\r\n",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300868,
      "choices": [
        {
          "id": 1,
          "text": "A & B"
        },
        {
          "id": 2,
          "text": "A, B & C"
        },
        {
          "id": 3,
          "text": "A, B & D"
        },
        {
          "id": 4,
          "text": "A & D"
        }
      ],
      "text": "<p>Which of the following drug useful in angina – PRIMARLY ACTING BY shifting the heart to use glucose oxidation and inhibiting fatty acid oxidation?</p><p>A. Trimetazidine</p><p>B. Perhexiline</p><p>C. Nicorandil</p><p>D. Ranolazine </p>",
      "unique_key": "Q300868",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (A)\r\n\r\n• A. Trimetazidine: This drug's primary and defining mechanism of action is the inhibition of 3-ketoacyl-CoA thiolase (3-KAT), directly inhibiting fatty acid oxidation and forcing the heart to use the more oxygen-efficient glucose pathway. It is a pure metabolic modulator.\r\n\r\n• B. Perhexiline: This drug's primary mechanism is the inhibition of carnitine palmitoyltransferase-1 (CPT-1), which blocks the transport of fatty acids into the mitochondria. This also forces a shift to glucose oxidation.\r\n\r\n• D. Ranolazine: This drug's primary anti-anginal mechanism is the inhibition of the late sodium current ($I_{Na}$). This reduces intracellular sodium and calcium overload, leading to decreased diastolic wall tension and improved myocardial perfusion. Its ability to inhibit fatty acid oxidation is a secondary or contributory effect.\r\nTherefore, the only drugs on this list that act primarily as metabolic modulators by shifting from fatty acid to glucose oxidation are Trimetazidine (A) and Perhexiline (B).\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300869,
      "choices": [
        {
          "id": 1,
          "text": "Sacubitril"
        },
        {
          "id": 2,
          "text": "Omapatrilat"
        },
        {
          "id": 3,
          "text": "Vericiguat"
        },
        {
          "id": 4,
          "text": "Nesiritide"
        }
      ],
      "text": "Which of the following drugs used in heart failure is associated with an increased risk of causing angioedema?",
      "unique_key": "Q300869",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (B)\r\n\r\nOmapatrilat is a vasopeptidase inhibitor that combines neprilysin and angiotensin-converting enzyme (ACE) inhibition. Unlike other drugs that act solely on the renin-angiotensin system, omapatrilat inhibits ACE and neprilysin simultaneously, leading to increased levels of bradykinin, a peptide responsible for vasodilation but also implicated in angioedema. This dual mechanism results in a higher incidence of angioedema compared to traditional ACE inhibitors or neprilysin inhibitors alone.\r\nSacubitril, when combined with valsartan (an ARB), also affects neprilysin but has a lower risk of angioedema than omapatrilat because it does not inhibit ACE directly.\r\nVericiguat and Nesiritide, used in heart failure for their vasodilatory effects, are not known to be associated with angioedema.\r\nTherefore, B. Omapatrilat carries the highest risk of angioedema among these options\r\n",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300870,
      "choices": [
        {
          "id": 1,
          "text": "1-b, 2-d, 3-c, 4-a"
        },
        {
          "id": 2,
          "text": "1-c, 2-a, 3-b, 4-d"
        },
        {
          "id": 3,
          "text": "1- c, 2- d, 3- b, 4- a"
        },
        {
          "id": 4,
          "text": "1- d, 2-a, 3- c, 4- d"
        }
      ],
      "text": "<p>Match the following cholesterol-lowering agents with their correct mechanisms of action:</p><p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/5303709_Pharma-3.png\"></p>",
      "unique_key": "Q300870",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (B)\r\n\r\n• Inclisiran is a synthetic siRNA that targets PCSK9 mRNA, reducing PCSK9 protein levels and thereby enhancing LDL receptor recycling to lower LDL cholesterol.\r\n\r\n• Evinacumab is a monoclonal antibody that inhibits ANGPTL3, a protein involved in lipid metabolism, leading to reduced LDL and triglycerides.\r\n\r\n• Bempedoic acid inhibits ATP citrate lyase, an enzyme upstream of HMG-CoA reductase in cholesterol biosynthesis, reducing cholesterol production.\r\n\r\n• Volanesorsen is an antisense oligonucleotide targeting apolipoprotein C-III mRNA, reducing triglyceride levels by enhancing lipolysis.\r\n",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300871,
      "choices": [
        {
          "id": 1,
          "text": "Ticagrelor"
        },
        {
          "id": 2,
          "text": "Dabigatran"
        },
        {
          "id": 3,
          "text": "Apixaban"
        },
        {
          "id": 4,
          "text": "Alteplase"
        }
      ],
      "text": "Andexanet alfa is useful for the reversal of the anticoagulant action of:",
      "unique_key": "Q300871",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (C)\r\n\r\nAndexanet alfa is a recombinant modified factor Xa protein that acts as a decoy receptor to bind and neutralize direct factor Xa inhibitors such as apixaban and rivaroxaban. By sequestering these inhibitors, it rapidly reverses their anticoagulant effects, making it useful in cases of life-threatening or uncontrolled bleeding.\r\n\r\n• Ticagrelor is an antiplatelet agent and is not reversed by andexanet alfa.\r\n\r\n• Dabigatran is a direct thrombin inhibitor reversed by a different agent (idarucizumab).\r\n\r\n• Apixaban is a factor Xa inhibitor, and its anticoagulant effect is reversed by andexanet alfa.\r\n\r\n• Alteplase is a thrombolytic agent and is not reversed by andexanet alfa.\r\n\r\nTherefore, andexanet alfa is specifically used for reversal of anticoagulation caused by factor Xa inhibitors like apixaban (Option C).\r\n",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300872,
      "choices": [
        {
          "id": 1,
          "text": "Oxcarbazepine"
        },
        {
          "id": 2,
          "text": "Lamotrigine"
        },
        {
          "id": 3,
          "text": "Topiramate"
        },
        {
          "id": 4,
          "text": "Valproate"
        }
      ],
      "text": "\r\nA 45-year-old female with focal epilepsy develops hyponatremia (serum sodium 125 mEq/L) with low plasma osmolality and high urine osmolality. Her current antiepileptic drug is most likely responsible for this condition via SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion). Which of the following antiepileptic drugs carries the highest risk of causing SIADH?",
      "unique_key": "Q300872",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (A)\r\n\r\n• Oxcarbazepine (and its parent drug carbamazepine) is well known to cause hyponatremia due to SIADH, especially in the elderly and at higher doses.\r\n\r\n• Lamotrigine, Topiramate, and Valproate are rarely associated with SIADH; topiramate may cause acidosis or nephrolithiasis, but not commonly SIADH.\r\n\r\n• Among the options, Oxcarbazepine has the strongest and most frequent association with SIADH\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300873,
      "choices": [
        {
          "id": 1,
          "text": "A & B"
        },
        {
          "id": 2,
          "text": "A, B & C"
        },
        {
          "id": 3,
          "text": "B & C"
        },
        {
          "id": 4,
          "text": "C & D"
        }
      ],
      "text": "<p>A 52-year-old patient is diagnosed with Amyotrophic Lateral Sclerosis (ALS). Which of the following drugs are approved or clinically used for the management of ALS?</p><p>A. Riluzole<br></p><p>B. Edaravone<br></p><p>C. Tofersen<br></p><p>D. Tetrabenazine</p>",
      "unique_key": "Q300873",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (B)\r\n\r\n• Riluzole – Approved for ALS; reduces glutamate excitotoxicity.\r\n\r\n• Edaravone – Approved for ALS; antioxidant that reduces oxidative stress.\r\n\r\n• Tofersen – Approved for SOD1-mutation ALS; antisense oligonucleotide.\r\n\r\n• Tetrabenazine – Used for Huntington’s chorea, not ALS\r\n",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300874,
      "choices": [
        {
          "id": 1,
          "text": "Lasmiditan"
        },
        {
          "id": 2,
          "text": "Ubrogepant"
        },
        {
          "id": 3,
          "text": "Rizatriptan"
        },
        {
          "id": 4,
          "text": "Erenumab"
        }
      ],
      "text": "A 35-year-old long-distance truck driver with frequent migraine attacks is being evaluated for acute treatment. He requires a medication that will not impair his driving ability. Which of the following migraine drugs requires specific caution in drivers due to its CNS effects?",
      "unique_key": "Q300874",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (A)\r\n\r\n• Lasmiditan is a selective 5-HT1F receptor agonist (not a triptan) that can cause significant dizziness, sedation, and driving impairment. Patients are advised not to drive for at least 8 hours after taking it.\r\n\r\n• Ubrogepant (gepant) and Rizatriptan (triptan) have minimal CNS sedative effects in most patients.\r\n\r\n• Erenumab is a monoclonal antibody (preventive) with no acute CNS effects.\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300875,
      "choices": [
        {
          "id": 1,
          "text": "Lamotrigine"
        },
        {
          "id": 2,
          "text": "Fluoxetine"
        },
        {
          "id": 3,
          "text": "Quetiapine"
        },
        {
          "id": 4,
          "text": "Lurasidone"
        }
      ],
      "text": "A patient with Bipolar Disorder (BPD), currently in a depressive episode, is being evaluated for treatment. Which of the following drugs should generally be avoided as monotherapy for depression in BPD due to the risk of inducing manic switch or lack of efficacy?",
      "unique_key": "Q300875",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (B)\r\n\r\n• Fluoxetine (an SSRI) used alone without a mood stabilizer in bipolar depression carries a significant risk of inducing mania or rapid cycling and is not recommended as monotherapy.\r\n\r\n• Lamotrigine is a mood stabilizer used for bipolar depression maintenance.\r\n\r\n• Quetiapine and Lurasidone are both approved for acute bipolar depression and do not carry the same switching risk as antidepressants when used alone.\r\n",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300876,
      "choices": [
        {
          "id": 1,
          "text": "Rett Syndrome"
        },
        {
          "id": 2,
          "text": "Hutchinson–Gilford Progeria Syndrome"
        },
        {
          "id": 3,
          "text": "Pain management"
        },
        {
          "id": 4,
          "text": "Treating pruritus in chronic kidney disease (CKD)"
        }
      ],
      "text": "The drug Suzetrigine is primarily indicated for which of the following conditions?",
      "unique_key": "Q300876",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (C)\r\n\r\n• Suzetrigine (formerly BHV-7000) is a potassium channel opener developed for the treatment of epilepsy and neuropathic pain.\r\n\r\n• It is not indicated for Rett syndrome (though other antiseizure drugs may be used symptomatically), progeria (lonafarnib is used), or CKD-associated pruritus (difelikefalin is used for that).\r\n\r\n• Its primary use in clinical development is for focal epilepsy and pain management, making pain management the most appropriate answer.\r\n",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300877,
      "choices": [
        {
          "id": 1,
          "text": "A & B"
        },
        {
          "id": 2,
          "text": "A & D"
        },
        {
          "id": 3,
          "text": "B & C"
        },
        {
          "id": 4,
          "text": "C & D"
        }
      ],
      "text": "<p>A 65-year-old male with type 2 diabetes and a recent hospitalization for heart failure with reduced ejection fraction (HFrEF) is being evaluated for ongoing antidiabetic therapy. His current HbA1c is 7.8%. Which of the following antidiabetic medications are considered beneficial and recommended in this clinical scenario?<br></p><p>A. Empagliflozin<br></p><p>B. Pioglitazone<br></p><p>C. Saxagliptin<br></p><p>D. Dapagliflozin</p>",
      "unique_key": "Q300877",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (B)\r\n\r\n• SGLT2 inhibitors (Empagliflozin and Dapagliflozin) have proven cardiovascular benefits and are recommended in patients with type 2 diabetes and heart failure, as they reduce heart failure hospitalizations and cardiovascular mortality.\r\n\r\n• Pioglitazone (a TZD) is generally avoided in heart failure due to fluid retention and increased risk of heart failure exacerbation.\r\n\r\n• Saxagliptin (a DPP-4 inhibitor) has been associated with an increased risk of heart failure hospitalization in some studies and is not considered beneficial.\r\n",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300878,
      "choices": [
        {
          "id": 1,
          "text": "Cabergoline"
        },
        {
          "id": 2,
          "text": "Somatrem"
        },
        {
          "id": 3,
          "text": "Pegvisomant"
        },
        {
          "id": 4,
          "text": "Mecasermin"
        }
      ],
      "text": "A 4-year-old child presents with severe short stature, hypoglycemic episodes, and facial dysmorphism. Investigations show low IGF-1 levels but markedly elevated growth hormone levels. Which drug is recommended for this condition?",
      "unique_key": "Q300878",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (D)\r\n\r\n1. Understanding Laron Syndrome:\r\no Laron Syndrome is a genetic disorder caused by a defective Growth Hormone (GH) receptor.\r\no The patient's pituitary gland produces plenty of GH (hence the high serum level), but the body's cells, particularly in the liver, cannot recognize or respond to it.\r\no Because the GH receptor is non-functional, the liver fails to produce its primary downstream product, Insulin-like Growth Factor 1 (IGF-1).\r\no IGF-1 is the hormone that actually mediates most of the growth-promoting effects of GH (like bone and cartilage growth). Therefore, the patient has severe IGF-1 deficiency.\r\n\r\n2. Rationale for the Correct Drug:\r\no D. Mecasermin: This drug is recombinant human Insulin-like Growth Factor 1 (rhIGF-1). The treatment strategy in Laron Syndrome is to bypass the defective GH receptor entirely and directly supply the missing hormone, IGF-1. Mecasermin replaces the deficient IGF-1, binds to IGF-1 receptors on target tissues, and stimulates the growth that the body's own GH cannot.\r\n\r\n3. Rationale for the Incorrect Options:\r\no A. Cabergoline: This is a dopamine agonist used to treat hyperprolactinemia or, in some cases, acromegaly (GH excess) by suppressing hormone secretion from a pituitary adenoma. It is irrelevant to this patient's condition.\r\no B. Somatrem: This (along with Somatropin) is a recombinant form of Growth Hormone (GH). Giving this patient more GH would be completely ineffective, as their problem is not a lack of GH but an inability to respond to it. This is proven by the failed IGF-1 generation test.\r\no C. Pegvisomant: This is a GH receptor antagonist (blocker). It is used to treat acromegaly (a condition of GH excess), where it blocks the overactive GH receptors to lower IGF-1 production. Using it in this patient would be counterproductive, as their receptors are already non-functional.\r\n",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300879,
      "choices": [
        {
          "id": 1,
          "text": "A & B"
        },
        {
          "id": 2,
          "text": "B & C"
        },
        {
          "id": 3,
          "text": "A & C"
        },
        {
          "id": 4,
          "text": " C & D"
        }
      ],
      "text": "<p>Identify the incorrect match regarding osteoporosis drug therapies and their adverse effects:<br></p><p>A. Zoledronate promotes osteoblast activity and causes erosive esophagitis<br></p><p>B. Raloxifene inhibits osteoclasts and causes DVT<br></p><p>C. Teriparatide inhibits osteoclasts and causes osteosarcoma<br></p><p>D. Denosumab inhibits osteoclasts and causes osteonecrosis of the jaw</p>",
      "unique_key": "Q300879",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (C) \r\n\r\nHere is a detailed explanation for each statement:\r\n\r\nA. Zoledronate promotes osteoblast activity and causes erosive esophagitis\r\n• This statement is INCORRECT.\r\n• Mechanism: The stated mechanism (\"promotes osteoblast activity\") is false. Zoledronate is a bisphosphonate, which is an anti-resorptive agent. Its primary mechanism is to inhibit osteoclast activity, leading to their apoptosis (cell death) and thereby reducing bone breakdown.\r\n• Adverse Effect: The stated adverse effect (\"causes erosive esophagitis\") is false for Zoledronate specifically. Erosive esophagitis is a well-known side effect of oral bisphosphonates (like Alendronate or Risedronate) due to direct irritation of the esophageal lining. Zoledronate is administered intravenously (IV), bypassing the gastrointestinal tract and thus does not cause this side effect.\r\n\r\nB. Raloxifene inhibits osteoclasts and causes DVT\r\n• This statement is CORRECT.\r\n• Mechanism: Raloxifene is a Selective Estrogen Receptor Modulator (SERM). It acts as an estrogen agonist on bone, which inhibits osteoclast activity and reduces bone resorption, similar to estrogen.\r\n• Adverse Effect: Acting as an estrogen agonist on coagulation factors, Raloxifene is known to increase the risk of thromboembolic events, such as Deep Vein Thrombosis (DVT) and pulmonary embolism.\r\n\r\nC. Teriparatide inhibits osteoclasts and causes osteosarcoma\r\n• This statement is INCORRECT.\r\n• Mechanism: The stated mechanism (\"inhibits osteoclasts\") is false. Teriparatide is a recombinant form of parathyroid hormone (PTH) and is an anabolic (bone-building) agent. When given in intermittent, low doses, it paradoxically stimulates osteoblast activity and increases bone formation. (This is the opposite of continuous high PTH, which does cause bone resorption).\r\n• Adverse Effect: The stated adverse effect (\"causes osteosarcoma\") is true. This is the FDA \"black box warning\" for Teriparatide, based on increased incidence in rat studies.\r\n\r\nD. Denosumab inhibits osteoclasts and causes osteonecrosis of the jaw\r\n• This statement is CORRECT.\r\n• Mechanism: Denosumab is a monoclonal antibody that binds to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). By blocking RANKL, it prevents the formation, function, and survival of osteoclasts, thereby powerfully inhibiting bone resorption.\r\n• Adverse Effect: Osteonecrosis of the Jaw (ONJ) is a rare but serious adverse effect associated with potent anti-resorptive therapies, including Denosumab and bisphosphonates\r\n",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300880,
      "choices": [
        {
          "id": 1,
          "text": "A-T, B-F, C-F, D-F, E-T "
        },
        {
          "id": 2,
          "text": "A-T, B-F, C-F, D-T, E-T "
        },
        {
          "id": 3,
          "text": "A-F, B-F, C-F, D-F, E-T "
        },
        {
          "id": 4,
          "text": "A-T, B-T, C-F, D-F, E-T"
        }
      ],
      "text": "<p>Identify the true (T) and false (F) statements from the list below, and select the correct corresponding option.<br><br>A. Omeprazole interferes with the metabolic activation of clopidogrel. <br><br>B. Alosetron is useful in the treatment of constipation-predominant irritable bowel syndrome (IBS-C).<br><br>C. Netupitant is a primary agent used in the treatment of GERD. <br><br>D. Tenapanor is a direct chloride channel activator. <br><br>E. Ustekinumab is approved for the treatment of Inflammatory Bowel Disease (IBD).<br><br><br></p>",
      "unique_key": "Q300880",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (A)\r\n\r\nRationale\r\n• A. Omeprazole interferes with the metabolic activation of clopidogrel. (TRUE)\r\no Clopidogrel is a prodrug that requires activation by the hepatic enzyme CYP2C19. Omeprazole is a potent inhibitor of CYP2C19, which significantly reduces the conversion of clopidogrel to its active form, thereby diminishing its antiplatelet effect.\r\n• B. Alosetron is useful in the treatment of constipation-predominant irritable bowel syndrome (IBS-C). (FALSE)\r\no Alosetron is a 5-HT3 antagonist. This mechanism slows colonic transit and increases fluid absorption. It is approved only for women with severe diarrhea-predominant IBS (IBS-D). A major side effect is constipation.\r\n• C. Netupitant is a primary agent used in the treatment of GERD. (FALSE)\r\no Netupitant is an NK1 (Neurokinin-1) receptor antagonist. It is used in combination with palonosetron (a 5-HT3 antagonist) for the prevention of chemotherapy-induced nausea and vomiting (CINV). It has no established role in treating GERD.\r\n• D. Tenapanor is a direct chloride channel activator. (FALSE)\r\no Tenapanor's mechanism is the inhibition of the sodium-hydrogen exchanger 3 (NHE3) in the gut. This reduces sodium absorption from the intestinal lumen, leading to water retention and an osmotic laxative effect. It is not a chloride channel activator (e.g., Lubiprostone, Linaclotide).\r\n• E. Ustekinumab is approved for the treatment of Inflammatory Bowel Disease (IBD). (TRUE)\r\no Ustekinumab is a monoclonal antibody that targets the p40 subunit of IL-12 and IL-23. It is FDA-approved for treating both major forms of IBD: Crohn's disease and Ulcerative Colitis\r\n",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 300881,
      "choices": [
        {
          "id": 1,
          "text": "Netarsudil promotes aqueous humor drainage primarily via the uveoscleral route. "
        },
        {
          "id": 2,
          "text": "Latanoprost promotes aqueous humor drainage primarily via the uveoscleral route"
        },
        {
          "id": 3,
          "text": "Pilocarpine promotes aqueous humor drainage primarily via the uveoscleral route"
        },
        {
          "id": 4,
          "text": "Dorzolamide promotes aqueous humor drainage primarily via the trabecular route"
        }
      ],
      "text": "Identify the one CORRECT statement regarding the mechanism of action of the following glaucoma medications:\r\n\r\n",
      "unique_key": "Q300881",
      "question_audio": null,
      "question_video": null,
      "map_id": null,
      "difficulty_level": "easy",
      "subjects_id": [],
      "solution": "Correct Answer (B)\r\nRationale\r\n• A. Incorrect. Netarsudil is a ROCK (Rho kinase) inhibitor. It increases aqueous humor outflow, but it does so by targeting the trabecular route (the conventional pathway).\r\n• B. Correct. Latanoprost is a prostaglandin F2$\\alpha$ analogue. Its primary mechanism is to increase aqueous humor outflow through the uveoscleral route (the unconventional pathway).\r\n• C. Incorrect. Pilocarpine is a cholinergic agonist (miotic). It increases outflow via the trabecular route by causing ciliary muscle contraction, which opens the meshwork.\r\n• D. Incorrect. Dorzolamide is a carbonic anhydrase inhibitor. Its mechanism is to decrease the production (inflow) of aqueous humor, not to promote drainage via a specific outflow pathway.\r\n",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}